Actively Recruiting
Study of Ubamatamab Alone and With Other Drugs in Adult Women With Platinum-Resistant Ovarian Cancer
Led by Regeneron Pharmaceuticals · Updated on 2026-09-14
297
Participants Needed
56
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating an experimental drug called ubamatamab in adults with advanced ovarian cancer, including primary peritoneal and fallopian tube cancers. The study aims to assess the safety, tolerability, and effectiveness of ubamatamab alone and in combination with other anti-cancer drugs such as bevacizumab, cemiplimab, fianlimab, REGN10597, and pegylated liposomal doxorubicin PLD. This phase 2 trial also investigates side effects, drug levels in the blood, and the bodys immune response to these treatments. Participants are assigned to different groups to receive ubamatamab either by itself or together with one or more of the combination drugs. These treatments are given according to the study protocol, and the study uses a randomized design without masking. The trial includes multiple experimental arms to explore various combinations involving ubamatamab and other agents. During the study, participants will undergo assessments over up to three years including tumor response evaluation using standardized criteria, blood tests to measure drug concentrations, and monitoring for any side effects or immune reactions. Researchers will track outcomes such as tumor shrinkage, disease control, progression-free survival, and the occurrence of side effects. This long-term follow-up helps understand the effects and safety of the study drug and its combinations.
CONDITIONS
Brief Title
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Research Team
C
Clinical Trials Administrator
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here